{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:16:15Z","timestamp":1773159375973,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.farma.2025.02.010","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T10:02:18Z","timestamp":1743242538000},"page":"286-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Off-label use of olaparib in uncommon tumor locations in patients with impaired homologous recombination genes"],"prefix":"10.1016","volume":"49","author":[{"given":"H\u00e9ctor Carlos","family":"Garc\u00eda-D\u00edaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Larrosa-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"G\u00f3mez-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"Cruellas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Farriols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.","family":"Carreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2025.02.010_bb0005","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2147\/OTT.S278092","article-title":"PARP inhibitor applicability: detailed assays for homologous recombination repair pathway components","volume":"15","author":"O'Sullivan Coyne","year":"2022","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.farma.2025.02.010_bb0010","unstructured":"Committee for Medicinal Products for Human Use. Lynparza-epar-product-information_en. [Internet]. Amsterdam (Netherlands): European Medicines Agency; 2024 [Accessed 23 January 2025]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lynparza-epar-product-information_en.pdf."},{"issue":"3","key":"10.1016\/j.farma.2025.02.010_bb0015","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.farma.2025.02.010_bb0020","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.farma.2025.02.010_bb0025","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.farma.2025.02.010_bb0030","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [Internet]. Bethesda (MD): U.S. National Cancer Institute; 2017. [Accessed 12 March 2024]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"issue":"15","key":"10.1016\/j.farma.2025.02.010_bb0035","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9737","key":"10.1016\/j.farma.2025.02.010_bb0040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.farma.2025.02.010_bb0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13048-023-01094-5","article-title":"Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status","volume":"16","author":"Wu","year":"2023","journal-title":"J Ovarian Res"},{"issue":"3","key":"10.1016\/j.farma.2025.02.010_bb0050","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ygyno.2015.03.042","volume":"137","author":"Coleman","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"S4","key":"10.1016\/j.farma.2025.02.010_bb0055","doi-asserted-by":"crossref","first-page":"S270","DOI":"10.1016\/j.annonc.2020.08.055","article-title":"77P clinical characteristics and therapeutic implications of PALB2 variants in patients with advanced solid tumors","volume":"31","author":"Gheeya","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.farma.2025.02.010_bb0060","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.2147\/OTT.S176914","article-title":"Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report","volume":"11","author":"Cheng","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.farma.2025.02.010_bb0065","first-page":"933","article-title":"Case report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate","volume":"12","author":"Zhou","year":"2022","journal-title":"Front Oncol"},{"issue":"18","key":"10.1016\/j.farma.2025.02.010_bb0070","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.21037\/atm-21-3681","article-title":"Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report","volume":"9","author":"Li","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.farma.2025.02.010_bb0075","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.2147\/OTT.S317514","article-title":"Remarkable response to olaparib in a patient with combined hepatocellular-cholangiocarcinoma harboring a biallelic BRCA2 mutation","volume":"14","author":"Su","year":"2021","journal-title":"Onco Targets Ther"},{"issue":"2","key":"10.1016\/j.farma.2025.02.010_bb0080","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1158\/1078-0432.CCR-22-2551","article-title":"Human metastatic cholangiocarcinoma patient-derived xenografts and tumoroids for preclinical drug evaluation","volume":"29","author":"Serra-Camprub\u00ed","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.farma.2025.02.010_bb0085","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12885-023-10772-y","article-title":"ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells toPARP inhibitors","volume":"23","author":"Parvin","year":"2023","journal-title":"BMC Cancer"},{"issue":"22","key":"10.1016\/j.farma.2025.02.010_bb0090","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.farma.2025.02.010_bb0095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaoncol.2022.5218","article-title":"Avelumab plus talazoparib in patients with BRCA1\/2- or ATM-altered advanced solid tumors: results from JAVELIN BRCA\/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial","volume":"9","author":"Schram","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.farma.2025.02.010_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101595","article-title":"Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): a multicentre, randomised, controlled, phase 2 trial","volume":"52","author":"Fennell","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.farma.2025.02.010_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102041","article-title":"Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study","volume":"8","author":"Joris","year":"2023","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.farma.2025.02.010_bb0110","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.embor.7400587","article-title":"p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene","volume":"7","author":"Arias-Lopez","year":"2006","journal-title":"EMBO Rep"},{"issue":"20","key":"10.1016\/j.farma.2025.02.010_bb0115","doi-asserted-by":"crossref","first-page":"9658","DOI":"10.1158\/0008-5472.CAN-07-0290","article-title":"RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors","volume":"67","author":"Martin","year":"2007","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.farma.2025.02.010_bb0120","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3390\/genes14051054","article-title":"POLE-mutant colon cancer treated with PD-1 blockade showing clearance of circulating tumor DNA and prolonged disease-free interval","volume":"14","author":"Bikhchandani","year":"2023","journal-title":"Genes (Basel)"},{"issue":"9","key":"10.1016\/j.farma.2025.02.010_bb0125","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/cncr.31951","article-title":"Ampullary cancer: evaluation of somatic and germline genetic alterations and association with clinical outcomes","volume":"125","author":"Wong","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.farma.2025.02.010_bb0130","unstructured":"ClinicalTrials.gov. A study to evaluate rucaparib in participants with solid tumors and with deleterious mutations in HRR genes (LODESTAR). [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2023. [Accessed March 12, 2024]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04171700."},{"issue":"1","key":"10.1016\/j.farma.2025.02.010_bb0135","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41698-023-00376-x","article-title":"Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge","volume":"7","author":"Keane","year":"2023","journal-title":"NPJ Precis Oncol"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634325000170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634325000170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:19:10Z","timestamp":1760213950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634325000170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1130634325000170"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2025.02.010","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Off-label use of olaparib in uncommon tumor locations in patients with impaired homologous recombination genes","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2025.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H).","name":"copyright","label":"Copyright"}]}}